(Q46326788)

English

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors

scientific article published on 16 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

Jourik A Gietema

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

author name string

Sunil Sharma

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

Elisabeth G de Vries

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

Jeffrey R Infante

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

Corina N Oldenhuis

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

Lin Yang

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

Sanela Bilic

7

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

Katie Parker

8

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

Michael Goldbrunner

9

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

Jeffrey W Scott

10

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

Howard A Burris

11

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

publication date

16 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

32

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

135-144

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

https://scigraph.springernature.com/pub.10.1007/s10637-013-9952-9

0 references

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

The receptor for the cytotoxic ligand TRAIL

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

On the TRAIL to apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

The clinical trail of TRAIL.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

TRAIL and cancer therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

Cancer phase I clinical trials: efficient dose escalation with overdose control.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

Dose‐Finding with Two Agents in Phase I Oncology Trials

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

Response to Neoadjuvant Chemotherapy in Breast Cancer Could be Predictable by Measuring a Novel Serum Apoptosis Product, Caspase-Cleaved Cytokeratin 18: A Prospective Pilot Study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9952-9

21 January 2018

Targeting apoptosis pathways in cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23589214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/23589214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-013-9952-9

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/23589214

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46326788&oldid=2144456310"